Understanding of Genetics by Men at Risk for Prostate Cancer
Mayo Clinic
Summary
With this greater certainty regarding prognosis, men with localized prostate cancer are now equipped with make better treatment planning decisions. This study is designed to investigate the understanding of prognostic genetic technology in African American and rural White men at risk for localized prostate cancer.
Description
Novel genomic technology, such as microarray analyses and next-generation sequencing, have improved the understanding of prostate cancer biology and prognosis. The National Comprehensive Cancer Network (NCCN), in 2016, recommended that patients and clinicians consider tissue-based genetic tests for localized prostate cancer. However, while much enthusiasm currently exits for the rapidly increasing field of genomic medicine, the use of multi-gene mRNA expression panels raises the potential for further divergence in prostate cancer treatment outcomes by race and low socioeconomic status. We know…
Eligibility
- Age range
- 40–95 years
- Sex
- Male
- Healthy volunteers
- Yes
Inclusion Criteria: * African-American or White men * Living in a rural or urban areas * Age 40 to 95 years old * Able and willing to provide informed consent * English-speaking * Willing to participate in the study. This study will use the United States Department of Agriculture Office of Rural Development's definition of rural, which is as a city or town that has a population less than 50,000 inhabitants to define rural. This study will use the United States Census Bureau's definition of urban, which is a city or town that has a population greater than 50,000 inhabitants to define urban.…
Interventions
- BehavioralFocus group analyses
Focus group audiotapes will be transcribed verbatim, and then entered into the qualitative data software package, NVivo 14 for analysis.
Locations (3)
- Mayo ClinicPhoenix, Arizona
- Mayo Clinic in FloridaJacksonville, Florida
- Mayo ClinicRochester, Minnesota